Subscribe To
Nkarta (nktx) rallies 112% as fda clears ind for lupus drug
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, nkx0...
October 18, 2023, 12:03 pm
Nkarta reports second quarter 2023 financial results and corporate highlights
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regi...
August 10, 2023, 11:01 am
Nkarta presents nkx019 clinical data at the european hematology association 2023 congress and 17th international conference on malignant lymphoma
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with nkx019 monot...
June 10, 2023, 2:47 pm
Nkarta to host conference call to discuss updated clinical data from nkx019 nk cell therapy program
Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX...
December 2, 2022, 9:02 pm
Nkarta to host conference call to discuss updated clinical data from nkx019 nk cell therapy program
Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET...
December 2, 2022, 4:02 pm
Nkarta: a promising natural killer cell play
The market has favorably appreciated Nkarta's recent readout of its NKX101 and nkx019 drug candidates, ...
May 20, 2022, 3:14 pm
Here is why nkarta is 40% up
Nkarta Inc. (NASDAQ: NKTX) is up 40% after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and ...
April 25, 2022, 12:51 pm